Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties.

@article{Argentieri1993ElectrophysiologicAA,
  title={Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties.},
  author={T. Argentieri and H. Troy and M. S. Carroll and C. M. Doroshuk and M. Sullivan},
  journal={Journal of cardiovascular pharmacology},
  year={1993},
  volume={21 4},
  pages={
          647-55
        }
}
CK-3579 (N-[4-[2-hydroxy-3-[[2-[4-(1H-inidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, HCL-[RS]), is a new class III antiarrhythmic agent with beta-adrenoceptor blocking properties shown to be effective in preventing ventricular arrhythmias in experimental animals. We examined the beta 1- and beta 2-adrenoceptor binding properties, cellular electrophysiology, and antiarrhythmic efficacy of CK-3579 and the two enantiomers CK-4000 (S) and CK-4001 (R). Both CK-3579 and CK-4000… Expand
11 Citations
Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257.
Characterization of the sensitivity of cardiac outwardly-rectifying K+ channels to class III antiarrhythmics: the influence of inhibitory sulfonamide derivatives
Design, synthesis and pharmacological screening of hybrid molecules as antihypertensives
The electrophysiologic effects of ersentilide on canine hearts.
Distinct modes of blockade in cardiac ATP-sensitive K+ channels suggest multiple targets for inhibitory drug molecules
What Should We Expect From the Next Generation of Antiarrhythmic Drugs?
Chapter 104 – New Antiarrhythmic Drugs
...
1
2
...